- Home
- TLRY vs TMCI Comparison
TLRY vs TMCI Comparison
Compare TLRY & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLRY
- TMCI
- Stock Information
- Founded
- TLRY N/A
- TMCI 2014
- Country
- TLRY Canada
- TMCI United States
- Employees
- TLRY N/A
- TMCI N/A
- Industry
- TLRY Medicinal Chemicals and Botanical Products
- TMCI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- TLRY Health Care
- TMCI Health Care
- Exchange
- TLRY Nasdaq
- TMCI Nasdaq
- Market Cap
- TLRY 637.2M
- TMCI 516.6M
- IPO Year
- TLRY 2018
- TMCI 2021
- Fundamental
- Price
- TLRY $0.43
- TMCI $6.82
- Analyst Decision
- TLRY Hold
- TMCI Hold
- Analyst Count
- TLRY 3
- TMCI 6
- Target Price
- TLRY $1.38
- TMCI $9.18
- AVG Volume (30 Days)
- TLRY 24.1M
- TMCI 494.0K
- Earning Date
- TLRY 04-08-2025
- TMCI 05-08-2025
- Dividend Yield
- TLRY N/A
- TMCI N/A
- EPS Growth
- TLRY N/A
- TMCI N/A
- EPS
- TLRY N/A
- TMCI N/A
- Revenue
- TLRY $826,656,000.00
- TMCI $210,819,000.00
- Revenue This Year
- TLRY $10.11
- TMCI $10.85
- Revenue Next Year
- TLRY $5.88
- TMCI $10.07
- P/E Ratio
- TLRY N/A
- TMCI N/A
- Revenue Growth
- TLRY 11.22
- TMCI 7.54
- 52 Week Low
- TLRY $0.41
- TMCI $3.92
- 52 Week High
- TLRY $2.31
- TMCI $11.33
- Technical
- Relative Strength Index (RSI)
- TLRY 34.40
- TMCI 41.89
- Support Level
- TLRY $0.41
- TMCI $6.94
- Resistance Level
- TLRY $0.52
- TMCI $7.73
- Average True Range (ATR)
- TLRY 0.03
- TMCI 0.52
- MACD
- TLRY 0.00
- TMCI 0.10
- Stochastic Oscillator
- TLRY 16.18
- TMCI 50.27
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.
About TMCI Treace Medical Concepts Inc.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.